FULC Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

As of 07/01/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/18/2019
Outstanding shares:  40,848,212
Average volume:  1,091,182
Market cap:   $200,156,239
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJDX8Z9
Valuation   (See tab for details)
PE ratio:   -2.24
PB ratio:   1.06
PS ratio:   11.80
Return on equity:   -47.46%
Net income %:   -529.15%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy